Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
134 hedge funds and large institutions have $1.03B invested in Global Blood Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 64 increasing their positions, 25 reducing their positions, and 18 closing their positions.
156% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 25
106% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 18
51% more call options, than puts
Call options by funds: $14M | Put options by funds: $9.27M
16% more funds holding
Funds holding: 116 → 134 (+18)
11% less capital invested
Capital invested by funds: $1.16B → $1.03B (-$127M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$43.6M |
| 2 |
O
OrbiMed
New York
|
+$32.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$29.3M |
| 4 |
BlackRock
New York
|
+$23.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSC
White Square Capital
London,
United Kingdom
|
-$53.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.9M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$9.02M |
| 4 |
YCMGA
York Capital Management Global Advisors
New York
|
-$4.24M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$3.34M |
GBT Hedge Fund Activity: Q2 2017 in Review
134 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2017, worth a combined $1.03B — down 11% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new GBT positions and 18 closed out — a net gain of 19 holders — while 64 added to existing stakes and 25 trimmed.
The largest buyer was State Street, adding an estimated $43.6M. The largest seller was White Square Capital, exiting entirely with an estimated $53.6M sold.
- 134 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2017, up from 116 in Q1 2017.
- Funds reported $1.03B of Global Blood Therapeutics, Inc. stock for Q2 2017, down 11% quarter-over-quarter.
- 37 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2017 and 18 closed out, a net change of +19 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q2 2017 was State Street, an estimated $43.6M added.
- The largest Global Blood Therapeutics, Inc. seller in Q2 2017 was White Square Capital, an estimated $53.6M sold.
Based on aggregated 13F filings for Q2 2017.